https://scholars.lib.ntu.edu.tw/handle/123456789/565417
標題: | STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa | 作者: | Gutschmidt K. Musumeci O. D?az-Manera J. YIN-HSIU CHIEN Knop K.C. Wenninger S. Montagnese F. Pugliese A. Tavilla G. Alonso-P?rez J. WUH-LIANG HWU Toscano A. Schoser B. |
關鍵字: | Alglucosidase alpha; Efficacy; Enzyme replacement therapy; Glycogen storage disease type 2; Long term follow-up; Pompe disease | 公開日期: | 2021 | 出版社: | Springer Science and Business Media Deutschland GmbH | 來源出版物: | Journal of Neurology | 摘要: | Background: Pompe disease is one of the few neuromuscular diseases with an approved drug therapy, which has been available since 2006. Our study aimed to determine the real-world long-term efficacy and safety of alglucosidase alfa. Methods: This multicenter retrospective study (NCT02824068) collected data from adult?Pompe disease?patients receiving ERT for at least 3?years. Demographics and baseline characteristics, muscle strength, lung function (FVC), walking capability (6MWT), and safety were assessed once a year. Evaluation was done on the group and individual levels, using quantitative linear models (t test) and general univariate linear models (ANOVA). Findings: Sixty-eight adult Pompe disease patients from four countries (Spain, Taiwan, Italy, Germany (STIG)) participated. The mean follow-up was 7.03?years ± 2.98. At group level in all outcome measures, an initial improvement followed by a secondary decline was observed. After 10?years, the 6MWT%pred showed the most sustained positive effect (p = 0.304). The MRC%max remained stable with a mild decline (p = 0.131), however, FVC%pred deteriorated significantly (p < 0.001) by 14.93% over 10?years of ERT. The progression rate of FVC%pred under ERT could be explained in most of the patients (83.5%) by the disease severity at baseline. Furthermore, our study shows a decline in the FVC combined with an increase in non-invasive and invasive ventilation requirements in adult Pompe disease patients?over time. Conclusions: The STIG real-world study confirms an initial efficacy of ERT in the first years with a secondary sustained decline in multiple outcome measures. Further efforts are required to establish a more valid long-term monitoring and improved therapies. ? 2021, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100513071&doi=10.1007%2fs00415-021-10409-9&partnerID=40&md5=5122e3e0f5c9d7fdfe76d03b098dbddf https://scholars.lib.ntu.edu.tw/handle/123456789/565417 |
ISSN: | 0340-5354 | DOI: | 10.1007/s00415-021-10409-9 | SDG/關鍵字: | alglucosidase alfa; anticoagulant agent; antihistaminic agent; corticosteroid; alpha glucosidase; GAA protein, human; adult; aged; anaphylaxis; antibody titer; Article; bronchospasm; cohort analysis; drug efficacy; drug safety; dyspnea; enzyme replacement; erythema; female; fever; flushing; follow up; forced vital capacity; Germany; glycogen storage disease type 2; human; invasive ventilation; Italy; limited mobility; lung embolism; lung function test; major clinical study; male; multicenter study (topic); muscle strength; nausea and vomiting; proteinuria; quantitative analysis; retrospective study; shivering; side effect; six minute walk test; skin anaphylaxis; Spain; Taiwan; walking; clinical trial; enzyme replacement; multicenter study; treatment outcome; Adult; alpha-Glucosidases; Enzyme Replacement Therapy; Germany; Glycogen Storage Disease Type II; Humans; Italy; Retrospective Studies; Spain; Taiwan; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。